Navigation Links
Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential
Date:12/10/2009

es on a "drug liking" scale.

The subjects reported neutral "drug liking" scores for placebo and positive "drug liking" scores for zolpidem and ketamine, which confirmed study validity. The subjective effects of the 20 mg lorcaserin dose were similar to those of placebo. "Drug liking" was significantly lower for the 40 mg and 60 mg lorcaserin doses as compared to zolpidem and ketamine, and subjects demonstrated significant disliking of these supratherapeutic doses of lorcaserin compared to placebo. The subjects' willingness to take lorcaserin again for recreational purposes was significantly lower for 40 mg and 60 mg doses as compared to placebo.

Data from the trial demonstrate that the risk for abuse associated with lorcaserin is very low and less than that of zolpidem or ketamine. At the supratherapeutic doses, lorcaserin was associated with distinct, primarily negative, subjective effects. Although the majority of subjects who took lorcaserin at the supratherapeutic doses in this trial reported adverse events, most often headache, only two subjects withdrew from the trial because of an adverse event.

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area involved in the control of appetite and metabolism. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central ner
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)...  Span-America Medical Systems, Inc. (NASDAQ:  SPAN) announced ... second quarter results on Thursday, April 30, after the ... will conduct a conference call at 10:00 a.m. ... financial and operating results for the second quarter ended ... conference call will be available online at ...
(Date:4/24/2015)... 24, 2015 Research and Markets ... addition of the "Lab Accessories Market ... Reservoir/Valve/Tubing/Wash Station) & End User (OEM/Biotechnology & ... to 2020" report to their offering. ... is expected to reach $504.7 million by ...
(Date:4/24/2015)... 24, 2015 The National Institute of ... National Institutes of Health [NIH])  provided grants totaling ... for the development of diagnostic tests for antibiotic-resistant ... at U.S. health facilities , the NIAID and ... multiplexed and effective tests using alternative methods to ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Kalorama: NIAID Rewards HAI Innovators with Grants 2Kalorama: NIAID Rewards HAI Innovators with Grants 3Kalorama: NIAID Rewards HAI Innovators with Grants 4
... Reportlinker.com announces that a new market ... , Reportlinker Adds Global Medical ... Sales Strategies and the Impact of Recession ... , Summary , "Global ...
... Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced ... L-DOS47 product development programs following pre-investigational new drug ("pre-IND") ... , Helix requested the pre-IND meetings in order to ... filings with the FDA. The meeting on Topical Interferon ...
Cached Medicine Technology:Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 2Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 3Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 4Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 5Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 6Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 7Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 8Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 9Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 10Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 11Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 12Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 13Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 14Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 2Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 3Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 4Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 5Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 6Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 7Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 8
(Date:4/26/2015)... 26, 2015 With the FCPX LUT B&W ... editors can quickly and easily add desaturated color grades ... a mathematical formula for modifying an image. The LUT changes ... table. This pack comes with 60 black and white CUBE ... contemporary black and white films. With the FCPX LUT ...
(Date:4/26/2015)... In an article published last month in ... biomechanics occurring during the use of handheld electronic devices such ... that use of a tablet increases mechanical demand on neck ... more than when the neck is in a neutral position. ... pointing out the potential hazards of overuse of mobile technology ...
(Date:4/25/2015)... Diversified Communications has announced the launch ... Integrative Healthcare Symposium Canada, as it’s titled, will ... Sheraton Parkway Toronto North in Ontario. , The ... most anticipated events of the year and will ... event aims to gather multi-disciplined practitioners from all ...
(Date:4/25/2015)... New York, New York (PRWEB) April 25, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) established for vaginal mesh lawsuits filed ... in the U.S. District Court, Southern District of ... April 9th, a Scheduling Conference was convened that ... the Plaintiffs’ Master Long Form Complaint. The Order ...
(Date:4/25/2015)... Gardant Management Solutions will lead ... operations, and sales and marketing at the LeadingAge ... be held from April 29 through May 1 ... largest eldercare association in Illinois. The statewide association ... adults, including senior housing, assisted living and supportive ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, a FCPX Effects Developer, Announced the Release of FCPX LUT B&W 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2
... EAST LANSING, Mich. Curcumin, a compound found in ... of a protein involved in Parkinson,s disease, says a ... led by Basir Ahmad, an MSU postdoctoral researcher, demonstrated ... cause of clumping, or aggregation, which is the first ...
... March 15, 2012, the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) celebrated ... for all employees in the Technische Sammlungen Dresden ... HZDR,s outstanding scientific achievements of the last year ... Mller-Steinhagen, Rector of the TU Dresden [Dresden University ...
... (LPS) has been found to elevate amyloid beta (Aβ) ... in learning. "We have found that after ... LPS administration) mice showed significant elevation in Aβ levels ... biology at Texas Christian University in Fort Worth. ...
... in St. Louis have shown that a new drug makes ... of the white blood cells. Instead of attacking these cells ... marrow and into the bloodstream, where they are more vulnerable ... leukemia cells from the blood," says Geoffrey L. Uy, MD, ...
... off, one in a white judogi (the traditional judo uniform) ... and lock arms, in what looks like an awkward dance, ... the mat. Judo and mixed martial arts have become ... taken note. The two fighters were actually filmed as part ...
... (Philadelphia) Intervention by peer mentors has a statistically significant ... diabetes, according to a study by researchers at the Perelman ... Philadelphia VA Center for Health Equity Research and Promotion (CHERP). ... 20th issue of the Annals of Internal Medicine. ...
Cached Medicine News:Health News:Curcumin shows promise in attacking Parkinson's disease 2Health News:Dresden's Helmholtz Center celebrates anniversary and presents HZDR awards 2Health News:Dresden's Helmholtz Center celebrates anniversary and presents HZDR awards 3Health News:Drug makes leukemia more vulnerable to chemo 2Health News:Drug makes leukemia more vulnerable to chemo 3Health News:Scientists measure how energy is spent in martial arts 2Health News:Penn researchers find mentoring provides health benefits for African American veterans with diabetes 2Health News:Penn researchers find mentoring provides health benefits for African American veterans with diabetes 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: